Document is current
Any future updates will be listed below
-
Authors
Dong, Han https://orcid.org/0009-0003-4975-8269
Ray, Arindam
Rotter, Lara K.
Wang, Jinhua
Grabski, Isabella
Mewada, Heemaja
Wang, Lulu
Huang, Kun https://orcid.org/0000-0002-9100-9638
Tian, Ye https://orcid.org/0000-0002-9655-7123
Meylan, Maxime
Barlow, Graham
Yu, Chenyang
Raundhal, Mahesh
Yoon, Sung-Hee
Nakhawa, Shreya https://orcid.org/0009-0000-3860-6209
Ding, Liya
Zhao, Jean J. https://orcid.org/0000-0002-4561-5688
Matulonis, Ursula A.
Foretz, Marc https://orcid.org/0000-0001-7017-9032
Wucherpfennig, Kai W. https://orcid.org/0000-0002-1829-302X
Irizarry, Rafael A. https://orcid.org/0000-0002-3944-4309
Wein, Marc N. https://orcid.org/0000-0002-6015-8147
Glimcher, Laurie H. https://orcid.org/0000-0002-4971-0404
- License Information
-
More Information
Article History
Received: 25 June 2025
Accepted: 1 April 2026
First Online: 20 May 2026
Competing interests
: L.H.G. is a former Director of Bristol–Myers Squibb, GlaxoSmithKline Pharmaceuticals and the Waters Corporation, and recently stepped down from the Board of Directors of Analog Devices, Inc. L.H.G. is a consultant for JP Morgan Healthcare and recently joined the Board of Directors of Behavior AI Scaled Insights, Inc. L.H.G. is a co-founder of a new company, Antero Biosciences, that is developing drugs for the prevention and management of anemia. J.W. is a consultant and equity holder for Soltego. K.W.W. serves on the scientific advisory boards of DEM BioPharma, Solu Therapeutics, D2M Biotherapeutics, DoriNano, Inc. and Nextechinvest. He is a co-founder of Immunitas Therapeutics and receives sponsored research funding from Fate Therapeutics. K.W.W. also holds equity in TScan Therapeutics. M.N.W. receives research funding from Biomarin, Angitia Biopharmaceuticals and Bayer for projects unrelated to those presented in this Article. M.N.W. previously received research funding from Radius Health to study SIK inhibitors for skeletal diseases and is a co-inventor on a pending patent (US patent application 16/333,546) regarding the use of SIK inhibitors for osteoporosis. L.H.G., H.D. and J.W. are coinventors on a pending patent (PCT/US2024/046255 in US, EP, CN and JP) regarding treatment of high-grade serous carcinoma. The remaining authors declare no competing interests.
